Key Details
Price
$6.20Annual EPS
-$31.04Annual ROE
-95.22%Beta
1.05Events Calendar
Next earnings date:
May 14, 2025Recent quarterly earnings:
Nov 13, 2024Recent annual earnings:
Mar 31, 2021Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Jan 03, 2024Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Tenax Therapeutics, Inc. (NASDAQ:TENX ) Guggenheim Healthcare Innovation Conference November 13, 2024 1:00 PM ET Company Participants Chris Giordano - President and CEO Stuart Rich - Chief Medical Officer Conference Call Participants Seamus Fernandez - Guggenheim Securities Seamus Fernandez Good afternoon, everybody. And welcome again to Guggenheim Securities Inaugural Healthcare Innovation Conference.
CHAPEL HILL, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it will participate in the Guggenheim Healthcare Innovation Conference in Boston, Massachusetts, from November 11-13, 2024. Tenax's CEO, Chris Giordano, will provide an update on the company and the ongoing development of levosimendan, in a session investors can attend live or via webcast.
Tenax Therapeutics (NASDAQ: TENX ) stock is soaring higher on Tuesday after the company announced the completion of an oversubscribed private placement for its shares. This oversubscribed private placement has Tenax Therapeutics expecting $100 million in gross proceeds.
CHAPEL HILL, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (the “Company” or “Tenax Therapeutics”), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it has entered into a securities purchase agreement for an oversubscribed private placement financing that is expected to result in total gross proceeds of approximately $100 million to the Company, before deducting placement agent fees and other private placement expenses.
Tenax Therapeutics (NASDAQ: TENX ) stock is falling hard on Thursday after the pharmaceutical company announced details for a public offering of its shares. That public offering has Tenax Therapeutics selling 1.6 million units.
Shares of pharmaceutical specialist Tenax Therapeutics (NASDAD: TENX ) are skyrocketing on Monday amid encouraging regulatory news. More specifically, with a focus on addressing cardiovascular and pulmonary diseases with high unmet medical need, Tenax has received clearance for its investigational new drug (IND) application for its pulmonary hypertension therapeutic.
Shares of Tenax Therapeutics surged over 300% after it announced the US Food and Drug Administration has reviewed and cleared its Investigational New Drug (IND) application for its hypertension candidate, TNX-103. The specialty pharmaceutical company said the FDA's enables it to proceed with the first of two Phase 3 studies for TNX-103 (oral Levosimendan) for the treatment of pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF).
FAQ
- What is the primary business of Tenax Therapeutics?
- What is the ticker symbol for Tenax Therapeutics?
- Does Tenax Therapeutics pay dividends?
- What sector is Tenax Therapeutics in?
- What industry is Tenax Therapeutics in?
- What country is Tenax Therapeutics based in?
- When did Tenax Therapeutics go public?
- Is Tenax Therapeutics in the S&P 500?
- Is Tenax Therapeutics in the NASDAQ 100?
- Is Tenax Therapeutics in the Dow Jones?
- When was Tenax Therapeutics's last earnings report?
- When does Tenax Therapeutics report earnings?
- Should I buy Tenax Therapeutics stock now?